Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 8/20 | 0.50 |
| ▸ | PPARA | Q07869 | 2/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | PPARD | Q03181 | 1/20 | 0.44 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.42 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3503430 | 0.91 | HIF1A (0.43) | MAOBMAPK13MAPK14 | |
| SCHEMBL3506683 | 0.89 | MAOB (0.56) | MAOB | |
| SCHEMBL4334882 | 0.88 | MAOB (0.54) | MAOBPPARAPPARGPPARDSPHK2 | |
| SCHEMBL5617706 | 0.86 | MAOB (0.55) | MAOBPPARAPPARGPPARDSPHK2 | |
| SCHEMBL4338672 | 0.85 | MAOB (0.51) | MAOBPPARAPPARDMAPK13MAPK14 | |
| SCHEMBL4337603 | 0.82 | MAOB (0.59) | MAOBPPARAPPARG | |
| SCHEMBL3508387 | 0.81 | MAOB (0.59) | MAOB | |
| SCHEMBL4340548 | 0.79 | MAOB (0.45) | MAOBMAPK13MAPK14 | |
| SCHEMBL4340508 | 0.79 | MAOB (0.53) | MAOB | |
| SCHEMBL4339548 | 0.77 | LTA4H (0.47) | MAOBPPARAPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070078172-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2007-04-05 | — | — | US | claimed |
| WO-2006138475-A2 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2006-12-28 | — | — | WO | claimed |
| US-6762320-B2 | MONOAMINE OXIDASE B INHIBITORS; ALZHEIMER'S DISEASE, SENILE DEMENTIA | HOFFMAN-LA ROCHE INC. | 2004-07-13 | — | — | US | claimed |
| US-20030232883-A1 | N-acylamino benzyl ether derivatives | HOFFMANN-LA ROCHE INC. | 2003-12-18 | — | — | US | claimed |
| EP-1511718-B1 | N-ACYLAMINOBENZENE DERVATIVES AS SELECTIVE MONOAMINE OXIDASE B INHIBITORS | HOFFMANN LA ROCHE (CH) | 2009-05-06 | — | — | EP | disclosed |
| CN-100482638-C | N-acylaminobenzene dervatives as selective monoamine oxidase b inhibitors | HOFFMANN LA ROCHE (CH) | 2009-04-29 | — | — | CN | disclosed |
| US-20070078172-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2007-04-05 | — | — | US | disclosed |
| WO-2006138475-A2 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2006-12-28 | — | — | WO | disclosed |
| US-7053245-B2 | N-acylamino benzyl ether derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-05-30 | — | — | US | disclosed |
| US-20050283019-A1 | N-acylamino benzyl ether derivatives | JOLIDON SYNESE | 2005-12-22 | — | — | US | disclosed |
| CN-1656057-A | N-acylaminobenzene dervatives as selective monoamine oxidase b inhibitors | HOFFMANN LA ROCHE (CH) | 2005-08-17 | — | — | CN | disclosed |
| EP-1511718-A1 | N-ACYLAMINOBENZENE DERVATIVES AS SELECTIVE MONOAMINE OXIDASE B INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-03-09 | — | — | EP | disclosed |
| US-20040210079-A1 | N-acylamino benzyl ether derivatives | JOLIDON SYNESE | 2004-10-21 | — | — | US | disclosed |
| US-6762320-B2 | MONOAMINE OXIDASE B INHIBITORS; ALZHEIMER'S DISEASE, SENILE DEMENTIA | HOFFMAN-LA ROCHE INC. | 2004-07-13 | — | — | US | disclosed |
| US-20030232883-A1 | N-acylamino benzyl ether derivatives | HOFFMANN-LA ROCHE INC. | 2003-12-18 | — | — | US | disclosed |
| WO-2003099763-A1 | N-ACYLAMINOBENZENE DERVATIVES AS SELECTIVE MONOAMINE OXIDASE B INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232883-A1 | N-acylamino benzyl ether derivatives | MAOB, MAOA, AOC2 | MAOB 1/4885PPARA 2845/4885PPARG 2379/4885 |
| US-20070078172-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | MAOB, MAOA, GPR119 | MAOB 1/4885PPARA 1635/4885PPARG 668/4885 |
| US-20040210079-A1 | N-acylamino benzyl ether derivatives | MAOB, MAOA, CBR1 | MAOB 1/4885PPARA 2492/4885PPARG 1963/4885 |
| US-20050283019-A1 | N-acylamino benzyl ether derivatives | MAOB, MAOA, AOC2 | MAOB 1/4885PPARA 3484/4885PPARG 2943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.